Over the past decade, nine gene therapy clinical trials for Parkinson's disease (PD) have
been initiated and completed. Starting with considerable optimism at the initiation of each …

An estimated 466 million people suffer from hearing loss worldwide. Sensorineural hearing
loss is characterized by degeneration of key structures of the sensory pathway in the …

Background Nerve growth factor (NGF) is an endogenous neurotrophic-factor protein with
the potential to restore function and to protect degenerating cholinergic neurons in …

Objective: In an effort to account for deficiencies in axonal transport that limit the
effectiveness of neurotrophic factors, this study tested the safety and feasibility, in …

Current therapies for the devastating damage caused by traumatic brain injuries (TBI) are
limited. This is in part due to poor drug efficacy to modulate neuroinflammation …

Substantial interest persists for developing neurotrophic factors to treat neurodegenerative
diseases. At the same time, significant progress has been made in implementing gene …

Clinical trials represent a critical avenue for new treatment development, where early
phases (I, I/II) are designed to test safety and effectiveness of new therapeutics or diagnostic …

Neurotrophic factors have long shown promise as potential therapies for age-related
neurodegenerative diseases. However, 20 years of largely disappointing clinical results …

Introduction Neurodegenerative diseases are those wherein the neurons in the brain or
peripheral nervous system lose their function, eventually culminating in neuronal death …

Divergent and concise total syntheses of two lycopodium alkaloids, lyconadins A and C
have been developed. The synthesis of lyconadin A, having potent neurotrophic activity …